Previous 10 | Next 10 |
Assembly Biosciences (NASDAQ:ASMB) announces the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer. Okazaki joined Assembly Bio in 2020 as chief legal and business officer responsible for leading and executing strategi...
SOUTH SAN FRANCISCO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that Sir Michael Houghton, PhD, has been appointed...
Shares of Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at $3.35, breaking its 52-week low. So far today approximately 322,000 shares have been exchanged, as compared to an average 30-day volume of 1.7 million shares. There is potential upside of 20.1% for shares of Assembly Biosc...
Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at a new 52-week low of $3.51. So far today approximately 322,000 shares have been exchanged, as compared to an average 30-day volume of 1.6 million shares. Potential upside of 15.0% exists for Assembly Biosciences Inc., based on a cur...
Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, there's another clinical c...
Assembly Biosciences Inc. (NASDAQ:ASMB) traded at a new 52-week low today of $3.56. Approximately 322,000 shares have changed hands today, as compared to an average 30-day volume of 1.5 million shares. Assembly Biosciences Inc. has overhead space with shares priced $3.58, or 12.1% below ...
Assembly Biosciences Inc. (NASDAQ:ASMB) traded at a new 52-week low today of $3.64. This new low was reached on below average trading volume as 241,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Over the past year, Assembly Biosciences Inc. ...
Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation. 60 mg AB-729 given once every four weeks had achieved a similar HBsAg decline fo...
Assembly Biosciences (ASMB) announces data from its three clinical-stage core inhibitor programs, vebicorvir (VBR or ABI-H0731), ABI-H2158 (2158), and ABI-H3733 (3733) at EASL Liver Congress 2021.ASMB shares up 3% premarket trading at $4.09. In an oral presentation, William Delaney,...
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced data from its three clinical-stage core inhibitor programs, ...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...